These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15190232)

  • 21. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.
    Innis RB; Seibyl JP; Scanley BE; Laruelle M; Abi-Dargham A; Wallace E; Baldwin RM; Zea-Ponce Y; Zoghbi S; Wang S
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11965-9. PubMed ID: 8265656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iodine-123 labelled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain.
    Kuikka JT; Akerman K; Bergström KA; Karhu J; Hiltunen J; Haukka J; Heikkinen J; Tiihonen J; Wang S; Neumeyer JL
    Eur J Nucl Med; 1995 Jul; 22(7):682-6. PubMed ID: 7498231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
    Rossi C; Genovesi D; Marzullo P; Giorgetti A; Filidei E; Corsini GU; Bonuccelli U; Ceravolo R
    Clin Neuropharmacol; 2017; 40(1):34-36. PubMed ID: 27941527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings.
    Evans AH; Costa DC; Gacinovic S; Katzenschlager R; O'sullivan JD; Heales S; Lee P; Lees AJ
    Mov Disord; 2004 Oct; 19(10):1232-6. PubMed ID: 15390012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT.
    Varrone A; Sansone V; Pellecchia MT; Amboni M; Salvatore E; De Michele G; Filla A; Barone P; Pappatà S; Salvatore M
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1343-9. PubMed ID: 18283454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain.
    Kuikka JT; Bergström KA; Ahonen A; Hiltunen J; Haukka J; Länsimies E; Wang S; Neumeyer JL
    Eur J Nucl Med; 1995 Apr; 22(4):356-60. PubMed ID: 7607268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.
    van Dyck CH; Malison RT; Jacobsen LK; Seibyl JP; Staley JK; Laruelle M; Baldwin RM; Innis RB; Gelernter J
    J Nucl Med; 2005 May; 46(5):745-51. PubMed ID: 15872345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.
    Gil-Navarro S; Lomeña F; Cot A; Lladó A; Montagut N; Castellví M; Bosch B; Rami L; Antonell A; Balasa M; Pavia J; Iranzo A; Molinuevo JL; Sánchez-Valle R
    Eur J Neurol; 2013 Nov; 20(11):1459-e126. PubMed ID: 23679075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry.
    Depboylu C; Maurer L; Matusch A; Hermanns G; Windolph A; Béhé M; Oertel WH; Höglinger GU
    Neuroimage; 2013 Oct; 79():191-200. PubMed ID: 23631981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.
    Donnemiller E; Heilmann J; Wenning GK; Berger W; Decristoforo C; Moncayo R; Poewe W; Ransmayr G
    Eur J Nucl Med; 1997 Mar; 24(3):320-5. PubMed ID: 9143472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.
    Schillaci O; Pierantozzi M; Filippi L; Manni C; Brusa L; Danieli R; Bernardi G; Simonetti G; Stanzione P
    Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1452-6. PubMed ID: 16151764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease.
    Benítez-Rivero S; Marín-Oyaga VA; García-Solís D; Huertas-Fernández I; García-Gómez FJ; Jesús S; Cáceres MT; Carrillo F; Ortiz AM; Carballo M; Mir P
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):122-9. PubMed ID: 22906618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT.
    Jakobson Mo S; Axelsson J; Stiernman LJ; Larsson A; Af Bjerkén S; Bäckström D; Kellgren TG; Varrone A; Riklund K
    Nucl Med Commun; 2022 Mar; 43(3):247-255. PubMed ID: 34908018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images.
    Kas A; Payoux P; Habert MO; Malek Z; Cointepas Y; El Fakhri G; Chaumet-Riffaud P; Itti E; Remy P
    J Nucl Med; 2007 Sep; 48(9):1459-67. PubMed ID: 17704252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopaminergic Correlates of Orthostatic Hypotension in de novo Parkinson's Disease.
    Umehara T; Oka H; Nakahara A; Shiraishi T; Sato T; Matsuno H; Komatsu T; Omoto S; Murakami H; Iguchi Y
    J Parkinsons Dis; 2021; 11(2):665-673. PubMed ID: 33361609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
    Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
    Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.